The study for personnlized medicine using sorafenib with genome analysis

The study for personnlized medicine using sorafenib with genome analysis - The study of sorafenib

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000017365

Enrollment

Registered

2015-05-01

Start date

2011-12-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma and renal cell carcinoma taking sorafenib

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients with hepatocellular carcinoma and renal cell carcinoma taking sorafenib

Exclusion criteria

Exclusion criteria: No

Design outcomes

Primary

Measure	Time frame
Gene (PXR,ABCG1, ABCG2,CYP3A4,CYP3A5) The serum concentration of sorafenib and the metabolites The serum components	—

Countries

Japan

Contacts

Public ContactHiroaki Yamaguchi

Tohoku university hospital Department of Pharmaceutical Sciences

yamaguchi@hosp.tohoku.ac.jp022-717-7528

Outcome results